Addition of Elotuzumab Prolongs Survival in Relapsed or Refractory Myeloma
Treatment with elotuzumab plus lenalidomide and dexamethasone (ERd) was associated with significant and clinically meaningful reductions in mortality risk, compared with lenalidomide and dexamethasone...
Fresh Frozen Plasma May Help Maintain Successful Pregnancy in Women With Congenital TTP
Prophylactic fresh frozen plasma (FFP) infusions may be necessary to replenish ADAMTS13 activity and maintain a successful pregnancy in expectant mothers with congenital thrombotic...
Smokeless Tobacco Linked to Subtherapeutic INR in Warfarin-Treated Patient
Failure to achieve a therapeutic international normalized ratio (INR) with warfarin was associated with chronic exposure to vitamin K-rich smokeless chewing tobacco in a...
Evaluating the TP53 State and Its Implications for Myelodysplastic Syndromes Outcomes
In a new study published in Nature Medicine, researchers evaluated the effect of the TP53 allelic state on the clinical presentation and outcomes of...
Tranexamic Acid for Gastrointestinal Bleeding: Time to HALT-IT?
Although tranexamic acid reduces the risks of surgical bleeding and bleeding-related death in patients with trauma, it does not reduce risk of death from...
Evaluating Post-Transplant Sorafenib Maintenance in FLT3-Mutated AML
For patients with acute myeloid leukemia (AML) and an FLT3-ITD mutation, maintenance treatment with the multitargeted tyrosine kinase inhibitor (TKI) sorafenib significantly prolonged relapse-free...
Inhaled Vaporized Cannabis Yields No Analgesic Benefit in Patients With SCD
Inhalation of vaporized cannabis did not significantly reduce self-reported pain levels or disease-related symptoms in adults with sickle cell disease (SCD) compared with placebo,...
Evaluating Selinexor in Patients With Relapsed/Refractory DLBCL
Oral selinexor demonstrated durable activity and a 28% response rate in patients with previously treated relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according...
Cutaneous Toxicities Are Underestimated in Patients With MPNs Receiving Hydroxyurea
A prospective study from Germany has found that, in patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs), treatment with hydroxyurea (hydroxycarbamide) is associated with a substantially...
Combination of Tafasitamab and Lenalidomide Leads to Durable Responses in Relapsed/Refractory DLBCL
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for hematopoietic cell transplantation, treatment with a combination of the...
Current Issue
November 2020 Bonus ASH Annual Meeting Preview Edition (Volume 6, Issue...
View issue flipbook
November 2020 Bonus ASH Annual Meeting Preview Edition
Volume 6, Issue 14This issue offers a behind-the-scenes look at this year's virtual annual meeting,...